CTC
AKCA

Central Trust Company’s Akcea Therapeutics Inc AKCA Stock Holding History

Central Trust Company’s Portfolio AKCA Stock Details AKCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-50
Closed -$1K – 1405
2017
Q3 		$1K Buy
+50
New +$926 ﹤0.01% 1220

Other funds holding AKCA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Central Trust Company's AKCA Position: Q4 2017 in Review

Central Trust Company sold out of Akcea Therapeutics Inc (AKCA) in Q4 2017, closing a stake of 50 shares — an estimated $1K sold.

Central Trust Company first reported a position in AKCA in Q3 2017 and held it in 1 quarter. The position peaked at $1K in Q3 2017. 58 funds tracked by Wall St. Rank hold AKCA as of Q4 2017.

  • Central Trust Company reported no remaining Akcea Therapeutics Inc position as of Q4 2017 after selling out during the quarter.
  • Central Trust Company sold 50 Akcea Therapeutics Inc shares in Q4 2017, an estimated $1K.
  • Central Trust Company first reported a position in Akcea Therapeutics Inc in Q3 2017 and held it in 1 quarter.
  • Central Trust Company's Akcea Therapeutics Inc position peaked at $1K in Q3 2017.
  • 58 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q4 2017.

Based on Central Trust Company's 13F filing for Q4 2017, filed 23 Jan 2018.